Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
NSE:GLAXO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.11
Current: 0.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of GlaxoSmithKline Pharmaceuticals was 0.11. The lowest was 0.00. And the median was 0.02.
NSE:GLAXO's Debt-to-EBITDA is ranked better than 97.39% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs NSE:GLAXO: 0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
GlaxoSmithKline Pharmaceuticals Debt-to-EBITDA Related Terms
GlaxoSmithKline Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAXO vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Debt-to-EBITDA of 0.02 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GlaxoSmithKline Pharmaceuticals. This is near median its historical median of 0.02. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #18 out of 689 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is GlaxoSmithKline Pharmaceuticals' Debt-to-EBITDA too high?
GlaxoSmithKline Pharmaceuticals' current Debt-to-EBITDA of 0.02 is near median its 10-year median of 0.02. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. GlaxoSmithKline Pharmaceuticals' value of 0.02 is 98.8% below this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #18 out of 689 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #18 out of 689 companies for Debt-to-EBITDA. This places GlaxoSmithKline Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. GlaxoSmithKline Pharmaceuticals' value of 0.02 is 98.8% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 1.64, GlaxoSmithKline Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current Debt-to-EBITDA of 0.02 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GlaxoSmithKline Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current Debt-to-EBITDA is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,639.49, compared to a current price of ₹2,610.70 — trading 1.1% below its estimated fair value. The current Debt-to-EBITDA is 0.02, which is near median its 10-year median of 0.02 and 98.8% below the Drug Manufacturers industry median of 1.64. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Debt-to-EBITDA is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,610.70 is trading 1.1% below its estimated GF Value™ of ₹2,639.49.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
Debt-to-EBITDA: 0.02 (near median its 10-year median of 0.02)
GF Value™: ₹2,639.49 vs. price of ₹2,610.70 (1.1% below fair value)
Industry Position: 98.8% below the Drug Manufacturers median (#18 of 689)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
